The Latest Breaking News from PhRMA

As the debate over mifepristone makes its way to the Supreme Court, the pharmaceutical industry has raised concerns that ruling against the FDA could chill the development of new drugs.

You might get the impression from the Biden administration's insulin price cut and its initiative allowing Medicare to negotiate over other pharmaceuticals that the drug pricing issue is finally being taken seriously in Washington.

Drugmakers will be required to pay Medicare back for price increases that outpace inflation. The industry is expected to put up a fight over implementation.

After decades of failed attempts, Democrats this month passed legislation that aims to reign in the soaring costs of drugs for some in the United States

A deal on the table in Congress would help deliver on a long-time promise: to make prescription drugs more affordable. It includes a $2,000 cap on out-of-pocket expenses for Medicare patients.

Interest groups are spending millions in hopes of blocking legislation allowing Medicare to demand lower prices for prescription drugs.

Senate Minority Leader Mitch McConnell says plans by Democrats to curb drug prices would place socialist price controls between Americans and the treatments they need

Hospitals and community and rural health clinics that serve low-income patients say drug manufacturers have threatened their financial stability by dramatically cutting back their participation in a federal drug discount program that saves those health providers millions of dollars a year.

Health economists and diabetes experts weigh in on Gaetz’s faulty cause-and-effect argument that "doesn't exist"

At the end of March, after the House passed a bill that would cap the cost of insulin at $35 per month for insured consumers, Rep. Matt Gaetz, R-Fla., tweeted about why he voted against the legislation.